Press releases
ADVITECH TO PRESENT AT BIOCONTACT CONFERENCE IN QUEBEC CITY
30 September 2008
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - September 30th, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) a life sciences and technology company developing evidence based natural health products, today announced that Dr. Charles Doillon MD, PhD. will be presenting a progress report on the company's IM technological platform for wound management. The Advitech presentation is scheduled to begin at 15:00 p.m. local time on Wednesday, October 1st in the Bellevue room at the Chateau Frontenac Hotel in Quebec City.
A fraction from the IM technological platform has demonstrated a dual bioactive property which could be served either to accelerate wound healing or to control collagen remodelling. "These latter characteristics are very important for the proper remodeling in wound repair and their simultaneous action in one single product would be a unique advantage of the Advitech's IM-Fraction technological platform" has indicated Dr. Charles Doillon M.D, PhD. who is piloting this program.
For the wound healing application, Advitech has a R&D program targeting the characterization of specific fractions and a toxicology program with additional in-vitro and in-vivo studies. This significant program should be completed by year end, or early 2009. As previously stated, the Company intends to seek a strategic partner to further develop the wound healing applications.
ABOUT DR. DOILLON:
A recipient of scientific and medical awards, Dr. Doillon is currently a Full Professor (Dept. Surgery) at Laval University, Quebec City, and Researcher at the Research Center of the Centre Hospitalier de l'Universite Laval (CHUL).
Dr. Doillon has authored and co-authored several scientific publications and communications in the domain of wound healing, collagen remodelling and was a pioneer in showing a correlation between collagen fiber distribution and biomechanics in wound tissues.
ABOUT ADVITECH INC. www.advitech.com:
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex® for the treatment of mild-to-moderate psoriasis.
Advitech has drawn up a research program to develop new applications related to wound healing. This development is derived from both its XP-828L and IM technological platforms.
-30-
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Advitech Inc.
Renaud Beauchesne, MBA | Serge Comeau |
President and Chief Executive Officer | Investor's relations |
418-686-7498, ext. 228 | 514-862-4160 |